Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adélaïde Doussau

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Medical Ethics|October 19, 2016
Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine researchAdélaïde Doussau, Christine Grady
Statistics in Medicine|September 11, 2013
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trialsAdélaïde Doussau, Rodolphe Thiébaut, Xavier Paoletti
BMJ Open|February 20, 2020
Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort studyBenjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman
Clinical Trials (London, England)|October 4, 2019
Benefit, burden, and impact for a cohort of post-approval cancer combination trialsBenjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman
Statistics in Medicine|June 26, 2015
Dose finding with longitudinal data: simpler models, richer outcomesXavier Paoletti, Adélaïde Doussau, Monia Ezzalfani, et al.
Clinical Trials (London, England)|October 25, 2021
Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trialsAdélaïde Doussau, Isha Agarwal, Tito Fojo, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding studyAnne Floquet, Adélaïde Doussau, Véronique Brouste, et al.
JAMA Internal Medicine|November 27, 2018
Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic ReviewCarole A Federico, Taiji Wang, Adélaïde Doussau, et al.
Clinical Trials (London, England)|October 24, 2023
The impact of feedback training on prediction of cancer clinical trial resultsAdélaïde Doussau, Patrick Kane, Jeffrey Peppercorn, et al.
Trials|February 28, 2014
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial designLaura Richert, Adélaïde Doussau, Jean-Daniel Lelièvre, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Medical Ethics|October 19, 2016
Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine researchAdélaïde Doussau, Christine Grady
Statistics in Medicine|September 11, 2013
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trialsAdélaïde Doussau, Rodolphe Thiébaut, Xavier Paoletti
BMJ Open|February 20, 2020
Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort studyBenjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman
Clinical Trials (London, England)|October 4, 2019
Benefit, burden, and impact for a cohort of post-approval cancer combination trialsBenjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman
Statistics in Medicine|June 26, 2015
Dose finding with longitudinal data: simpler models, richer outcomesXavier Paoletti, Adélaïde Doussau, Monia Ezzalfani, et al.
Clinical Trials (London, England)|October 25, 2021
Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trialsAdélaïde Doussau, Isha Agarwal, Tito Fojo, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding studyAnne Floquet, Adélaïde Doussau, Véronique Brouste, et al.
JAMA Internal Medicine|November 27, 2018
Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic ReviewCarole A Federico, Taiji Wang, Adélaïde Doussau, et al.
Clinical Trials (London, England)|October 24, 2023
The impact of feedback training on prediction of cancer clinical trial resultsAdélaïde Doussau, Patrick Kane, Jeffrey Peppercorn, et al.
Trials|February 28, 2014
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial designLaura Richert, Adélaïde Doussau, Jean-Daniel Lelièvre, et al.
Pageof 2